Pasithea Therapeutics Welcomes Dr. Rebecca Brown to Advisory Board
Pasithea Therapeutics Welcomes Dr. Rebecca Brown to Advisory Board
MIAMI, Sept. 03, 2024 -- Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotechnology company, has announced the appointment of Dr. Rebecca Brown, M.D., Ph.D., as a member of its Scientific Advisory Board. This move reinforces the company’s commitment to advancing its groundbreaking therapy, PAS-004, aimed at treating neurofibromatosis type 1 (NF1) and other related conditions.
Dr. Rebecca Brown's Expertise in Neurofibromatosis
Dr. Brown currently serves as the Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital and as an Assistant Professor in the Department of Neurology's Division of Neuro-Oncology. Her wealth of knowledge and clinical experience in NF1 will provide significant insights to Pasithea as it progresses with PAS-004.
Significant Contributions to NF1 Research
With her extensive background as an investigator in numerous NF1 research projects, Dr. Brown has focused on cutaneous and plexiform neurofibromas. She has a prolific publication record in esteemed scientific journals and regularly shares her expertise at national and international conferences.
Comments from Leadership
“We are honored to have Dr. Brown, an internationally recognized NF1 authority, join our Scientific Advisory Board,” stated Dr. Tiago Reis Marques, Pasithea’s CEO. Dr. Brown’s experience will play a crucial role in the forthcoming Phase 1/2a clinical trial for PAS-004, enhancing the company’s developmental strategy.
Dr. Brown's Vision for PAS-004
Expressing her enthusiasm for the new role, Dr. Brown remarked, “I look forward to assisting with the development of PAS-004, a next-generation macrocyclic MEK inhibitor with promising preclinical data for NF1. This treatment has the potential to meet significant unmet medical needs and stands out from similar drugs due to its unique profile.”
A Closer Look at PAS-004
PAS-004 is characterized as a small molecule allosteric inhibitor of MEK 1/2 in the MAPK signaling pathway. Abnormal activation of this pathway can drive the proliferation of cancer cells and contribute to various diseases, including NF1. By inhibiting MEK, PAS-004 aims to induce cell death and limit tumor growth, addressing limitations posed by existing FDA-approved MEK inhibitors.
Potential Benefits of PAS-004
One of the standout features of PAS-004 is its macrocyclic structure, potentially leading to improved pharmacokinetic properties and enhanced safety profiles. Designed to offer a longer half-life and better dosing flexibility, the compound aims to ensure both effective treatment and patient compliance.
The Role of Pasithea Therapeutics
Pasithea is dedicated to researching and developing innovative therapies for central nervous system disorders and genetic syndromes like RASopathies. Backed by a talented team of experts, the company strives to create new molecules targeting neurological diseases, including NF1, solid tumors, and amyotrophic lateral sclerosis (ALS).
Frequently Asked Questions
What is Pasithea Therapeutics focused on?
Pasithea Therapeutics focuses on developing innovative treatments for central nervous system disorders and genetic syndromes.
Who is Dr. Rebecca Brown?
Dr. Rebecca Brown is a board-certified adult neuro-oncologist specializing in Neurofibromatosis, appointed to the Scientific Advisory Board of Pasithea.
What is PAS-004?
PAS-004 is a macrocyclic MEK inhibitor aimed at treating neurofibromatosis type 1 and potentially improving treatment efficacy and patient compliance.
How does PAS-004 differ from current treatments?
PAS-004 aims to provide a better safety profile and therapeutic window than currently available MEK inhibitors, enhancing overall treatment outcomes.
What are the upcoming plans for Pasithea?
Pasithea is planning to initiate a Phase 1/2a clinical trial for PAS-004 as part of its ongoing drug development efforts.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Education ERP Market Growth Projected to USD 75.84 Billion
- UK Home Prices Expected to Rise, Boosting First-Time Buyer Affordability
- UC Asset LP Announces Management-Driven Stock Buyback Plan
- Ukrenergo Board Members Resign Over Politically Motivated Dismissal
- US Dollar Index Emerges as Key Factor for European Markets
- Bybit Powered by SATOS Launches Exclusive Trading Contest
- Heritage Environmental Services Welcomes Patrick Schultz as Chief Officer
- VSG Achieves Major Milestone with Coinstore Listing Today
- Bitcoin (BTC) Poised to Break $60,000 Barrier Soon
- DSCVR Celebrates 1 Million Unique Monthly Visitors Milestone
- Axiom Medical Welcomes Kevin Campbell as CFO to Lead Growth
- CaringBridge Welcomes New Board Members and Leadership Roles
- Healthcare Digital Twins Market to Surge 25.70% Growth Rate
- Ulta Beauty Faces Challenges: Time to Seize Investment Opportunities
- Top Three High-Yield Dividend Stocks to Buy Now
- Trinity Biotech Welcomes Adrian Donohue as CCO
- US Stock Market Faces Challenges Amid Job Data Insights
- Industrial Automation Market to Reach USD 377.9 Billion by 2032
- Assisted Living Locators' Inspiring Initiative for Alzheimer's Month
- Florida Crystals® Marks Organic Month with Milestones and New Packaging
- U.S. Pain Foundation Launches #SolvePainTogether Initiative
- GSE Worldwide Receives Strategic Investment to Fuel Growth
- Connected Agriculture Market Expected to Reach USD 16.88 Billion
- Growing Demand for Pick to Light Solutions Transforming Industries
- Global Four-Wheeler Tires Market Set to Reach $365.5 Billion
Recent Articles
- UK Home Prices Expected to Rise, Boosting First-Time Buyer Affordability
- Corporate Profit Challenges: Earnings Outlook for 2025
- Trinity Biotech Welcomes Adrian Donohue as CCO
- U.S. Pain Foundation Launches #SolvePainTogether Initiative
- GSE Worldwide Receives Strategic Investment to Fuel Growth
- Understanding Nexans S.A. Share Capital and Voting Rights
- Coloplast A/S Share Trading Insights for Board and Executives
- Plumas Bank Unveils 2024 Corporate Citizenship Insights
- ThreatHunter.ai Launches Free Cybersecurity Tool for Businesses
- Celebree School Launches Campaign to Celebrate Literacy Month
- Mount Logan Capital Inc. Expands Workforce with New Hire
- PTC Welcomes Rob Bernshteyn to the Board of Directors
- GEN3 Silicon-Anode Batteries Surpass Graphite by 40% Capacity
- NKGen Biotech Set to Showcase Innovations at Investment Conference
- 4 Undervalued Stocks to Consider for Future Growth Potential
- US Stock Futures Drop as Labor Data Week Begins
- Skyharbour Launches New Drilling Program at Moore Uranium Project
- MiNK Therapeutics to Showcase Innovations at Global Conference
- Elevation Oncology Highlights Upcoming H.C. Wainwright Conference
- Freight Technologies Successfully Reduces Outstanding Debt
- Emergent BioSolutions Enhances Financial Stability with Refinancing
- Ashland Inc. Concludes Nutraceuticals Business Sale Agreement
- Lithium Ionic Appoints David D’Onofrio to Board of Directors
- U.S. Steel Shares Drop Amid Concerns Over Ownership Shift
- Hudson Valley Cancer Center Partners with New York Cancer Specialists